- Home
- VTVT vs ONCY Comparison
VTVT vs ONCY Comparison
Compare VTVT & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- ONCY
- Stock Information
- Founded
- VTVT 2015
- ONCY 1998
- Country
- VTVT United States
- ONCY Canada
- Employees
- VTVT N/A
- ONCY N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- ONCY Pharmaceuticals and Biotechnology
- Sector
- VTVT Health Care
- ONCY Health Care
- Exchange
- VTVT Nasdaq
- ONCY Nasdaq
- Market Cap
- VTVT 56.7M
- ONCY 49.1M
- IPO Year
- VTVT 2015
- ONCY 1999
- Fundamental
- Price
- VTVT $21.94
- ONCY $0.52
- Analyst Decision
- VTVT Strong Buy
- ONCY Strong Buy
- Analyst Count
- VTVT 2
- ONCY 3
- Target Price
- VTVT $35.50
- ONCY $4.33
- AVG Volume (30 Days)
- VTVT 9.3K
- ONCY 235.1K
- Earning Date
- VTVT 05-27-2025
- ONCY 05-14-2025
- Dividend Yield
- VTVT N/A
- ONCY N/A
- EPS Growth
- VTVT N/A
- ONCY N/A
- EPS
- VTVT N/A
- ONCY N/A
- Revenue
- VTVT $1,017,000.00
- ONCY N/A
- Revenue This Year
- VTVT N/A
- ONCY N/A
- Revenue Next Year
- VTVT N/A
- ONCY N/A
- P/E Ratio
- VTVT N/A
- ONCY N/A
- Revenue Growth
- VTVT N/A
- ONCY N/A
- 52 Week Low
- VTVT $12.12
- ONCY $0.47
- 52 Week High
- VTVT $29.01
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- VTVT 57.22
- ONCY 39.98
- Support Level
- VTVT $20.12
- ONCY $0.54
- Resistance Level
- VTVT $21.52
- ONCY $0.65
- Average True Range (ATR)
- VTVT 1.23
- ONCY 0.03
- MACD
- VTVT -0.09
- ONCY -0.00
- Stochastic Oscillator
- VTVT 67.00
- ONCY 5.50
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.